Price Movement and Daily Trading Range
On 6 Jan 2026, Venus Remedies closed at ₹769.00, down 1.69% from the previous close of ₹782.25. The stock traded within a range of ₹749.00 to ₹798.80 during the day, showing intraday volatility but maintaining a position well above its 52-week low of ₹272.20. The 52-week high stands at ₹848.90, indicating that the current price is approximately 9.5% below the peak, suggesting some consolidation after a strong rally.
Technical Indicator Overview
The technical landscape for Venus Remedies reveals a complex picture. The Moving Average Convergence Divergence (MACD) remains bullish on both weekly and monthly charts, signalling sustained upward momentum in the medium to long term. However, the Relative Strength Index (RSI) presents a bearish outlook on weekly and monthly timeframes, indicating potential overbought conditions or weakening momentum in the near term.
Bollinger Bands suggest a mildly bullish stance on weekly and monthly charts, reflecting moderate price expansion and volatility within an upward channel. Daily moving averages continue to support a bullish trend, reinforcing the stock’s short-term strength. The Know Sure Thing (KST) oscillator aligns with the MACD, showing bullish signals on weekly and monthly scales.
Conversely, Dow Theory and On-Balance Volume (OBV) indicators show no clear trend on weekly and monthly charts, implying a lack of decisive directional conviction from broader market participation and price action confirmation.
Shift in Technical Trend
Recent analysis indicates a shift from a fully bullish technical trend to a mildly bullish one. This subtle change suggests that while the stock retains an upward bias, caution is warranted as momentum indicators like RSI point to potential short-term corrections or consolidation phases. The divergence between MACD and RSI highlights a scenario where price momentum remains positive but may be losing some steam.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Long-Term Performance Outpaces Benchmarks
Venus Remedies has delivered exceptional returns over extended periods, vastly outperforming the Sensex. The stock’s 1-year return stands at an impressive 141.29%, compared to the Sensex’s 7.85%. Over three years, Venus Remedies surged 325.45%, while the Sensex gained 41.57%. The five-year and ten-year returns are even more striking, at 341.07% and 505.99% respectively, dwarfing the Sensex’s 76.39% and 234.01% gains.
Shorter-term returns also show resilience, with a 1-month gain of 3.19% versus a Sensex decline of 0.32%, and a 1-week return of 1.18% outperforming the Sensex’s 0.88%. Year-to-date, both Venus Remedies and the Sensex have posted modest gains of 0.26%, reflecting a cautious start to the calendar year.
Mojo Score Upgrade and Market Capitalisation
Reflecting the evolving technical and fundamental outlook, Venus Remedies’ Mojo Score was upgraded to 80.0 on 1 Jan 2026, elevating its Mojo Grade from Buy to Strong Buy. This upgrade underscores increased confidence in the stock’s growth prospects and technical strength. The company holds a Market Cap Grade of 4, indicating a mid-sized market capitalisation within its sector.
Sector Context and Industry Positioning
Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies benefits from robust industry tailwinds including rising healthcare demand, innovation in drug development, and expanding export opportunities. The sector’s overall momentum supports the stock’s technical profile, although sector-specific risks such as regulatory changes and pricing pressures remain pertinent.
Technical Outlook and Investor Considerations
Investors should note the mixed signals from technical indicators. The bullish MACD and KST suggest that the medium to long-term trend remains intact, while the bearish RSI warns of potential short-term pullbacks or sideways movement. The mildly bullish Bollinger Bands and daily moving averages provide additional support for a cautiously optimistic stance.
Given the absence of clear trends in Dow Theory and OBV, volume and price action confirmation are lacking, which may result in increased volatility or range-bound trading in the near term. Traders may consider monitoring key support levels near ₹749.00 and resistance around ₹798.80 to gauge breakout or breakdown scenarios.
Curious about Venus Remedies Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Summary and Strategic Implications
Venus Remedies Ltd stands at a technical crossroads, with momentum indicators signalling a transition to a mildly bullish phase after a sustained rally. The stock’s strong long-term performance and recent Mojo Grade upgrade to Strong Buy reinforce its appeal for growth-oriented investors. However, caution is advised given the bearish RSI and lack of volume confirmation, which may lead to short-term volatility.
Investors should weigh the stock’s impressive historical returns and sector fundamentals against the current technical nuances. A disciplined approach involving monitoring key technical levels and broader market conditions will be essential to capitalise on potential upside while managing downside risks.
About MarketsMOJO Ratings
MarketsMOJO’s comprehensive rating system integrates technical, fundamental, and market data to provide actionable insights. Venus Remedies’ current Mojo Score of 80.0 and Strong Buy grade reflect a favourable outlook supported by robust technical momentum and solid fundamentals within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
